Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $128.4, while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ARKQ | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $529.65 |
52-Week Low | $95.28 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $127.85, up 3.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting its exposure to SpaceX and defense stocks. Support and resistance levels indicate key price zones for near-term movement.
The outlook for ARKQ is supported by long-term themes in AI and robotics, though high RSI levels suggest caution. Risks include sector volatility and reliance on disruptive tech stocks. Analyst sentiment is mixed, with some recommending accumulation during dips for growth-oriented investors.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
